

08-26-02

TECH CENTER 1600/2900

AUG 27 2002

RECEIVED
#3/5/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Jerome B. Zeldis

Express Mail No.: EL 500 575 618 US

Confirmation No.: 5112

Serial No.: 09/734,460

Group Art Unit: 1615

Filed: December 11, 2000

Examiner: Evans, Charesse L.

For: METHODS AND COMPOSITIONS FOR THE
PREVENTION AND TREATMENT OF
ATHEROSCLEROSIS, RESTINOSIS AND RELATED
DISORDERS

Attorney Docket No.: 9516-018

RESPONSE TO RESTRICTION REQUIREMENT UNDER 37 C.F.R. § 1.142

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This responds to the Office Action, mailed July 25, 2002. Claims 1-31 are pending in the subject application.


A Request for Species Election has been entered for the present application. The Request for Species Election requires the election of a specific TNF inhibitor.

Applicants respectfully elects, with traverse, 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-amino-isoindoline which reads on claims and 1, 2, 4, 5, and 7-31. 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline is disclosed in the specification at page 10, line 12; and in Example 5.1 (page 26, lines 13-32). Furthermore, Applicants reserve the right to prosecute the non-elected subject matter in one or more subsequent divisional or continuing application(s).

No fee is believed to be due with this response. But should any fee be due, please charge the required amount to Pennie & Edmond's Deposit Account No. 16-1150.

Respectfully submitted,

Date: August 22, 2002


Anthony M. Insogna 35,203
(Reg. No.)
PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090